Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

OMNI-Lab Smoothing the Way to Expanded Newborn Screening at GSTS Pathology

Published: Monday, September 09, 2013
Last Updated: Monday, September 09, 2013
Bookmark and Share
Laboratory management software ensure that babies are not only screened within days of birth for the five established life-threatening diseases of infancy, but also for a further five rare conditions.

Integrated Software Solutions Ltd has announced the latest implementation of its OMNI-Lab Newborn Screening management suite, this time at GSTS Pathology LLP, the unique and innovative joint venture between Guy’s and St Thomas’ and King’s College Hospital NHS Foundation Trusts and Serco plc.

OMNI-Lab software is at the heart of a system that facilitates the safe and efficient management of bloodspots, taken by heel prick for screening from thousands of newborn infants each year in the South East Thames region (approx. 60,000 live births p.a.).

The screening either indicates that the infants are not suspected of having any of five serious diseases of infancy, or alerts paediatricians to the need for further testing and/or possible treatment.

Prior to implementing OMNI-Lab, GSTS had been using a bespoke LIMS based on a custom-written and since unsupported Microsoft™ Access 97™ database.

Staff were concerned that the database was at increasing risk of data loss or corruption - unthinkable given the critically-important nature of the data being acquired and stored.

In addition, the system was rapidly becoming obsolete in the face of new standards and was unable to interface with various laboratory analyzers. So tenders were invited from several providers and Integrated Software Solutions, the developer of OMNI-Lab, was selected.

Analie Booth, Service Delivery Manager – Biochemical Sciences at the time, stated: “We chose OMNI-Lab for its good electronic links, the fact that it future-proofed us and we liked its flexibility.”

Unlike previous customers for OMNI-Lab, who have usually opted for an off-the-peg solution, GSTS decided to get right under the skin of the system and build their own version from scratch. That meant several people learning how to write SQL and first they had to be trained by ISS.

Analie explains: “We’ve got a system now that’s bespoke for us, but which is fully supported by ISS. We’ve built up the capability in house such that we’ve got experts on site and don’t have to wait for ISS to come up with the solutions to problems for us - we can start working on them ourselves, which is a massive bonus. Having said that, we’ve had a lot of support from the ISS guys both in Winchester, here in the UK and in Australia and that’s ongoing.”

She added: “Although the implementation hasn’t been without teething problems, we’re getting there and we feel an awful lot safer than we did previously. We’ve also got interfaces to all our analyzers, something we didn’t have before. In phase two of the project we’re looking to introduce messaging with child health and maternity units through an N3 secure data connection, allowing us to download patient details and populate our database automatically.”

GSTS is currently taking part in a pilot study for expanded newborn screening, so in addition to the usual five tests they are also screening for five additional but rare conditions: Glutaric Aciduria Type 1 (GA1), Homocystinuria [pyridoxine unresponsive] (HCU), Isovaleric Acidemia (IVA), Maple Syrup Urine Disease (MSUD) and Long Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency (LCHADD.

Analie comments: “As this is a pilot project we are not required to report the results of the extra tests back to the Child Health Records Department. At the moment we simply record the results and suppress them so they are not sent out to clinicians, but are available internally for statistical analysis.”

Analie observes that GSTS is constantly reviewing processes and that includes what is happening with OMNI-Lab so that, before manual checks are removed, the system is as safe as it possibly can be.

She concludes: “OMNI-Lab has made us a lot safer overall and we have much more confidence in what’s happening with our processes. Phase two of the project will set the seal on OMNI-Lab’s effectiveness for us.”

Project Manager David Doran signed off for GSTS: “GSTS and Integrated Software Solutions (ISS) recently worked together to replace our existing newborn screening lab IT system with OMNI-Lab’s. The ISS Project Manager joined us in regular team meetings which brought about a very cohesive approach to meeting deadlines and making sure resources were available. We found ISS to have a ‘can-do’ approach to our project and they were very supportive in getting the job done. Completing this project as ‘one team’ ensured the project was delivered on time and under budget and will be an exemplar for our future projects.”

Alex Anderson, Managing Director of Integrated Software Solutions, noted: “What GSTS has done with OMNI-Lab illustrates perfectly just how versatile and therefore powerful it is – whether a lab wants to take an off-the-shelf solution straight from us or customize the suite to a high degree. It’s particularly exciting for us to be helping GSTS play its part in the Expanded Newborn Screening study, which is surely another ringing endorsement for OMNI-Lab in itself.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Lab-on-a-Chip Offers Promise for TB and Asthma Patients
A device to mix liquids using ultrasonics is the first and most difficult component in a miniaturized system for low-cost analysis of sputum from patients with pulmonary diseases such as tuberculosis and asthma.
Protein Related to Long Term Traumatic Brain Injury Complications Discovered
NIH-study shows protein found at higher levels in military members who have suffered multiple TBIs.
Urine Proteins Point to Early-Stage Pancreatic Cancer
A combination of three proteins found at high levels in urine can accurately detect early-stage pancreatic cancer, researchers at the BCI have shown.
Researcher Discovers Trigger of Deadly Melanoma
New research sheds light on the precise trigger that causes melanoma cancer cells to transform from non-invasive cells to invasive killer agents, pinpointing the precise place in the process where "traveling" cancer turns lethal.
Crystal Clear Images Uncover Secrets of Hormone Receptors
NIH researchers gain better understanding of how neuropeptide hormones trigger chemical reactions in cells.
New Tool Uses 'Drug Spillover' to Match Cancer Patients with Treatments
Researchers have developed a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker (KAR) predicts what genetics are truly driving the cancer in any population of cells and chooses the best "kinase inhibitor" to silence these dangerous genetic causes of disease.
HIV Susceptibility Linked to Little-Understood Immune Cell Class
High levels of diversity among immune cells called natural killer cells may strongly predispose people to infection by HIV, and may be driven by prior viral exposures, according to a new study.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!